title: Octenidine hydrochloride for the care of central venous catheter insertion sites in severely immunocompromised patients.
abstract: OBJECTIVE
  To determine the efficacy and tolerability of octenidine hydrochloride, a non-alcoholic skin antiseptic, for the care of central venous catheter (CVC) insertion sites.
  
  
  METHODS
  Prospective, observational study.
  
  
  METHODS
  Bone marrow transplantation unit of a university hospital.
  
  
  METHODS
  All consecutive patients with a nontunneled CVC were enrolled prospectively after informed consent.
  
  
  METHODS
  Octenidine hydrochloride (0.1%) was applied for disinfection at the CVC insertion site during dressing changes. The following cultures were performed weekly as well as at the occurrence of any systemic inflammatory response syndrome criteria: cultures of the skin surrounding the CVC entry site, cultures of the three-way hub connected to the CVC, blood cultures, and cultures of the CVC tip on removal. Enhanced microbiological methods (skin swabs of a 24-cm2 standardized area, roll plate, and sonication of catheter tips) were applied.
  
  
  RESULTS
  One hundred thirty-five CVCs were inserted in 62 patients during the study period and remained for a mean period of 19.1 days, corresponding to 2,462 catheter-days. Bacterial density at the insertion site declined substantially over time, and most cultures became negative 2 weeks after insertion. Only 6 patients had a documented catheter-related bloodstream infection. The incidence density was 2.39 catheter infections per 1,000 catheter-days. No side effects were noted with application of the antiseptic.
  
  
  CONCLUSIONS
  Disinfection with a skin antiseptic that contains octenidine hydrochloride is highly active and well tolerated. It leads to a decrease in skin colonization over time and may be a new option for CVC care.
authors.affiliation: Division of Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Tietz
authors.forename: Reno
authors.initials: R
authors.lastname: Frei
authors.forename: Marc
authors.initials: M
authors.lastname: Dangel
authors.forename: Dora
authors.initials: D
authors.lastname: Bolliger
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Passweg
authors.forename: Alois
authors.initials: A
authors.lastname: Gratwohl
authors.forename: Andreas E
authors.initials: AE
authors.lastname: Widmer
mesh_terms: D000328:Adult; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007097:Imines; D016867:Immunocompromised Host; D017053:Infection Control; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011725:Pyridines / Q000627:therapeutic use*; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000891:Anti-Infective Agents, Local; D007097:Imines; D011725:Pyridines; C034213:octenidine